Related Experiment Videos
Superparamagnetic iron oxide: detection of focal liver lesions at high-field-strength MR imaging
S H Duda1, M Laniado, A F Kopp
1Department of Diagnostic Radiology, Eberhard-Karls-Universität Tübingen, Germany.
Abstract:
AMI-25 was evaluated at 1.5 T as a superparamagnetic iron oxide contrast agent for the liver. Sixteen patients with up to five suspected focal liver lesions were examined with T1-, proton-density-, and T2-weighted spin-echo sequences before and after intravenous administration of AMI-25 (15 mumol/kg iron). The contrast-to-noise ratio (C/N) increased from 1.8 to 3.5 on 600/15 (TR msec/TE msec) images and from 1.7 to 7.9 on 2,500/15 images after AMI-25 administration (P < .01). C/N did not change significantly on 2,500/90 images. Two blinded readers counted the number of lesions visible on unenhanced and contrast-enhanced images, with the 32 sets of images of the 16 patients presented in random order. Both readers identified more lesions on AMI-25-enhanced images, but the difference was not statistically significant (P > .05). Two patients reported minor side effects (flushing, sensation of heat, lower back pain). On the basis of the results obtained in a limited number of patients, the authors conclude that at 1.5 T, AMI-25 does not significantly improve the detection of focal liver lesions on conventional spin-echo images.
Insights
Superparamagnetic iron oxide contrast agent AMI-25 did not significantly improve focal liver lesion detection on conventional MRI scans. While contrast-to-noise ratios improved, lesion visibility did not reach statistical significance in this study.
Area of Science:
- Radiology
- Medical Imaging
- Hepatology
Background:
- Focal liver lesions require accurate detection for diagnosis and management.
- Superparamagnetic iron oxide (SPIO) contrast agents offer potential for enhanced liver imaging.
- Evaluating novel contrast agents like AMI-25 is crucial for improving diagnostic capabilities.
Purpose of the Study:
- To assess the efficacy of AMI-25 as a superparamagnetic iron oxide contrast agent for liver lesion detection at 1.5 Tesla.
- To evaluate the impact of AMI-25 on contrast-to-noise ratios (C/N) in liver MRI.
- To determine if AMI-25 enhances the visibility of focal liver lesions on conventional spin-echo sequences.
Main Methods:
- A study involving 16 patients with suspected focal liver lesions.
- Acquisition of T1-, proton-density-, and T2-weighted spin-echo MRI sequences before and after AMI-25 administration (15 mumol/kg iron).
- Quantitative analysis of C/N changes and qualitative assessment of lesion detection by two blinded readers.
Main Results:
- Significant increases in C/N were observed on 600/15 and 2,500/15 images post-AMI-25 (P < .01).
- No significant change in C/N was noted on 2,500/90 images.
- While both readers identified more lesions on enhanced images, the difference was not statistically significant (P > .05).
- Minor side effects were reported in two patients.
Conclusions:
- At 1.5 T, AMI-25 did not significantly improve the detection of focal liver lesions using conventional spin-echo MRI sequences.
- Despite improvements in contrast-to-noise ratios, the clinical utility for lesion detection remains limited in this patient cohort.
- Further research with larger sample sizes may be warranted to fully elucidate the potential of AMI-25.